
AIM Stock Forecast & Price Target
AIM Analyst Ratings
Bulls say
AIM ImmunoTech Inc. exhibits a positive outlook driven by consistently favorable data from various clinical studies, including significant results from its Phase 2a study demonstrating Ampligen's potential in treating metastatic colorectal cancer. In February 2024, the company further validated its position with encouraging outcomes from a Phase 2 study focused on Ampligen for post-COVID conditions. The ongoing advancements in research and development indicate strong catalysts for the stock, reflecting its potential in addressing critical medical needs for types of cancers and viral diseases.
Bears say
AIM ImmunoTech Inc. reported a net loss of $3.3 million for the latest period, resulting in an EPS of $(1.57), surpassing prior estimates and signaling underperformance relative to expectations. The company also faced liquidity and balance sheet risks, alongside significant concerns regarding the efficacy and regulatory approval of its product candidates, which further compound its financial vulnerabilities. Additionally, the broader market sentiment toward biotechnology investments, coupled with potential competition and shifting healthcare priorities, adds layers of uncertainty that detract from a favorable financial outlook for the company.
This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.
AIM Analyst Forecast & Price Prediction
Start investing in AIM
Order type
Buy in
Order amount
Est. shares
0 shares